Zacks Investment Research upgraded Aptose Biosciences Inc (NASDAQ:APTO) to Hold in a report released today.
- Updated: October 11, 2016
Yesterday Aptose Biosciences Inc (NASDAQ:APTO) traded 5.22% higher at $2.39. The company’s 50-day moving average is $2.18 and its 200-day moving average is $2.47. The last closing price is down -3.84% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 29,362 shares of the stock traded hands, down from an average trading volume of 33,785
Zacks Investment Research has upgraded Aptose Biosciences Inc (NASDAQ:APTO) to Hold in a report released on 10/11/2016.
Previously on 6/13/2016, Roth Capital reported on Aptose Biosciences Inc (NASDAQ:APTO) increased the target price from $4.00 to $8.00. At the time, this indicated a possible upside of 1.70%.
See Chart Below
Aptose Biosciences Inc has a 52 week low of $1.92 and a 52 week high of $6.40 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokers have issued a report on the company. The average stock price target is $9.01 with 2 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Aptose Biosciences Inc (NASDAQ:APTO)
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.